DTRM-555 for Chronic Lymphocytic Leukemia

Mayo Clinic, Jacksonville, FL
Chronic Lymphocytic Leukemia+4 More ConditionsDTRM-555 - Drug
All Sexes
What conditions do you have?

Study Summary

This trial will evaluate a new oral combination of targeted drugs, called DTRM-555, for patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin's lymphoma.

Eligible Conditions
  • Chronic Lymphocytic Leukemia (CLL)
  • Non-Hodgkin's Lymphoma
  • Follicular Lymphoma
  • Richter's Transformation

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 6, 12 and 24 months

24 hours
Plasma Exchange
24 months
Complete Responses (CR) and Partial Responses (PR) with DTRM-555 in the five disease-specific cohorts
Therapeutic procedure
Month 24
Overall Response Rate (ORR) with DTRM-555 in the five disease-specific cohorts

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.

Trial Design

1 Treatment Group

Disease-specific cohorts
1 of 1

Experimental Treatment

120 Total Participants · 1 Treatment Group

Primary Treatment: DTRM-555 · No Placebo Group · Phase 2

Disease-specific cohorts
Experimental Group · 1 Intervention: DTRM-555 · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 6, 12 and 24 months

Who is running the clinical trial?

Zhejiang DTRM BiopharmaLead Sponsor
3 Previous Clinical Trials
81 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are expected to live for at least 12 more weeks.
You are able to swallow pills and keep them down.
You have been diagnosed with a type of cancer called R/R CLL or other B-cell neoplasms (ABC DLBCL, GCB DLBCL, Richter's transformation, tFL) and there are no approved treatments available for your condition. Alternatively, you have been diagnosed with non-Hodgkin's lymphoma, and standard therapy has not worked for you.

Frequently Asked Questions

What prior research efforts have been made with respect to DTRM-555?

"Currently, there are 179 experiments being conducted for DTRM-555. 26 of these trials are in the late stages, Phase 3. Although most studies take place in Hamilton, Ontario, 6803 other clinical sites across the world have also taken part in researching this new treatment option." - Anonymous Online Contributor

Unverified Answer

How many individuals have joined the trial thus far?

"Affirmative. Data from clinicaltrials.gov confirms that this research endeavour, initially posted on April 24th 2020, is actively recruiting volunteers. 120 individuals need to be sourced from 8 separate institutions." - Anonymous Online Contributor

Unverified Answer

What potential hazards should be taken into account when handling DTRM-555?

"Despite the absence of clinical data backing its efficacy, our team at Power have evaluated DTRM-555 to be moderately safe with a score of 2." - Anonymous Online Contributor

Unverified Answer

What ailments has DTRM-555 been clinically proven to help mitigate?

"DTRM-555 is a commonly utilized remedy for dealing with kidney transplant rejection. Additionally, this medication may be of benefit to those suffering from waldenstrom macroglobulinemia, lung issues, and advanced carcinoid tumor." - Anonymous Online Contributor

Unverified Answer

Are recruiting efforts underway to include participants in this trial?

"Affirmative. Clinicaltrials.gov confirms that enrollment for this clinical trial is open, with the original post dating back to April 24th 2020 and last updated on April 28th 2022. The research team is looking for 120 individuals across 8 medical centres." - Anonymous Online Contributor

Unverified Answer

How many sites are actively engaged in managing this research endeavor?

"This trial is recruiting subjects at institutions such as University of Pennsylvania Abramson Cancer Center in Philadelphia, Duke Cancer Institute in Durham, and Memorial Sloan Kettering Cancer Centre in New York. In addition to these three sites, there are 8 additional locations taking part in the study." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.